Sanofi-Aventis gets exclusive licence to OBT cancer antibody
This article was originally published in Scrip
Executive Summary
Oxford BioTherapeutics (OBT), a privately held UK biotechnology company developing targeted therapeutic antibodies for cancer, has licensed one of its preclinical programmes exclusively to Sanofi-Aventis.